CLINICAL PILOT-STUDY ON REPEATED SYSTEMAT ICALLY USE OF HEPARIN, VANCOMYCIN AND COLIMYCIN LOCKED FLUSH SOLUTION FOR CENTRAL INTRAVENOUS TOTALLY IMPLANTED CATHETER IN CANCEROLOGY

With an anti-infectious and an antithrombotic prophylaxis aims, a lock ed flush solution including heparin and vancomycin, was used systemati cally for implantable venous access system for each patient, from janu ary to april 1995. Since the 6th of april 1995, in order to widen the antibiotic spectrum on Gram negative bacteriae, we added colimycin at the flush solution. In 1995, 342 hospitalised patients held this type of venous access and received chemotherapy and/or radiochemotherapy fo r cancer, Two thousand six hundred thirty three manipulations were don e, 575 with the first flush solution, 2058 with the second. During the year, 15 implantable access system (4,4 %) were considered as infecte d, only 3 (0,9 %) were removed in the first period. The infectious rat e seemed to be stable, but the bacterial assessment to be modified bet ween the two periods. The Gram negative bacterial infections seemed to decrease with colimycin addition (33% versus 50%). These results must be confirmed by a long term and/or randomized study.